Why the study?
Do levels of insulin-like growth factors in tumors and ascites predict objective clinical response to neoadjuvant chemotherapy in patients with advanced ovarian cancer?
Do levels of insulin-like growth factors in tumors and ascites predict objective clinical response to neoadjuvant chemotherapy in patients with advanced ovarian cancer?
The level of IGF-I in ascites may serve as an independent predictor of objective clinical response to neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Answers are grounded in this paper and cite their sources.
Low ascites IGF-I associated with neoadjuvant response; leaves open whether measurement can guide therapy in advanced ovarian cancer.
Purpose: Tumor cell growth and sensitivity to chemotherapy depend on many factors, among which insulin-like growth factors (IGFs) may play important roles. The aim of the present study was to evaluate the levels of insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) in primary tumors and ascites as predictors of response to neoadjuvant chemotherapy in ovarian cancer (OC) patients. Materials and Methods: Tumor tissue samples and ascitic fluid were obtained from 59 patients with advanced OC. The levels of IGF-I, IGF-II, IGFBP-3, IGFBP-4 and PAPP-A were determined using ELISA kits. Taking into account the data on expression of these IGF-related proteins and outcome, logistic regression was performed to identify predictors of response to neoajuvant chemotherapy. Results: Human ovarian tumors expressed IGFs, IGFBP-3, IGFBP-4 and PAPP-A and these proteins were also present in ascites fluid and associated with its volume. IGFs and IGFBPs in ascites and soluble PAPP-A might play a key role in ovarian cancer progression . However, levels of proteins of the IGF system in tumors were not significant predictors of objective clinical response (oCR). Univariate analysis showed that the level of IGF-I in ascites was the only independent predictor for oCR. Conclusion: The level of IGF-I in ascites was shown to be an independent predictor of objective clinical response to chemotherapy for OC patients treated with neoadjuvant chemotherapy and debulking surgery.
No takes yet. Share an insight, caveat, or question.
Yunusova et al. (2016) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: